Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3Sarcoma 2Head & Neck 2Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 10Stomach Neoplasms 6Ovarian Neoplasms 4Colorectal Neoplasms 4Salivary Gland Neoplasms 3Pancreatic Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasms 1

Interventions

pembrolizumab 23Paclitaxel 23Carboplatin 15Specimen Handling 13Bevacizumab 12Magnetic Resonance Spectroscopy 10Doxorubicin 8Biopsy 8lenvatinib 7Taxes 7olaparib 6Letrozole 6Fulvestrant 6Cisplatin 6dostarlimab 5Nivolumab 5Gemcitabine 5abemaciclib 4X-Rays 4Trastuzumab 4Oxaliplatin 4Medroxyprogesterone Acetate 4Immunoglobulin G 4Fluorouracil 4Docetaxel 4trastuzumab deruxtecan 3palbociclib 3ipatasertib 3durvalumab 3Tirzepatide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Endometrial Neoplasms × trastuzumab deruxtecan × 90 days × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07124000 2026-05-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡